EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serum Hepatocyte Growth Factor Predicts Outcomes in Non‐Acetaminophen Drug‐Induced Acute Liver Failure

Tao Wang iD, Silvia M Bacot, Kamai Patterson, Devira Friedman, Caroline Taylor, Huixiao Hong, Jie Liu, Mark I Avigan iD, Paul Hayashi iD, Jody A Rule iD, William M Lee iD, Jorge Rakela iD und 2 weitere

Liver International · 2026-11 · 46 (11)

DOI: 10.1111/liv.70895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 01.10.2026. Verfasst von Tao Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmaceutical Quality Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Liver Failure, Acute, Hepatocyte Growth Factor, Chemical and Drug Induced Liver Injury. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The US Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Regenerative capacity and inflammatory responses are key determinants of outcome in acute liver failure (ALF). However, their prognostic significance in non‐acetaminophen drug‐induced liver injury with acute liver injury or ALF (non‐APAP‐DILI‐ALI/ALF) remains poorly defined. We aimed to identify biomarkers of regeneration and inflammation associated with clinical outcomes in this population.

Methods

We evaluated clinical laboratory parameters and circulating biomarkers in 79 patients with non‐APAP‐DILI‐ALI/ALF (20 with ALI, 59 with ALF) and 19 healthy donors. We used multivariable logistic regression to identify independent predictors of 21‐day transplant‐free survival among these patients. These predictors were used to create a composite model that was compared with the Model for End‐Stage Liver Disease (MELD) score.

Results

Markers reflecting hepatic synthetic dysfunction (TBIL, INR, MELD) were strongly associated with the outcomes, whereas aminotransferases were not. HGF levels were markedly elevated in non‐APAP‐DILI‐ALI/ALF patients versus healthy donors (5070 ± 4001 vs. 276 ± 581 pg/mL; p < 0.001), increased with injury severity, and were highest in patients who died or underwent transplantation (6421 ± 4359 vs. 4102 ± 3456 pg/mL; p = 0.009). Among inflammatory mediators, only interleukin‐6 showed a modest association with outcome. We developed an H‐Score based on the three variables independently associated with survival on multivariable analysis: HGF (odds ratio, 1.0002; p = 0.048), TBIL and INR. The H‐Score outperformed MELD overall (area under the curve, 0.819 vs. 0.713) and in ALF only patients (0.811 vs. 0.643; p = 0.040).

Conclusions

HGF provides independent prognostic value beyond standard measures in non‐APAP‐DILI‐ALF. The H‐Score may improve risk stratification over the MELD score and warrants validation in a prospective cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Failure, AcuteHepatocyte Growth FactorChemical and Drug Induced Liver InjuryHumansFemaleBiomarkersMaleMiddle AgedAdultPrognosisLogistic ModelsSeverity of Illness IndexMultivariate AnalysisPredictive Value of TestsCase-Control Studies

Stichwörter der Autor:innen

drug‐induced liver failuredrug‐induced liver injuryhepatocyte growth factorinflammatory cytokines and chemokinesprognostic biomarker

Substanzen

Hepatocyte Growth FactorBiomarkersHGF protein, human

Autor:innen und Institutionen

  • Office of Pharmaceutical Quality Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Division of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Division of Gastroenterology and Hepatology, University of Texas Southwestern, Dallas, Texas, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.

ORCID-Profile: Tao Wang, Mark I Avigan, Paul Hayashi, Jody A Rule, William M Lee, Jorge Rakela, Minjun Chen

Förderung

  • The US Food and Drug Administration

Zitieren

APA

Wang, T., Bacot, S. M., Patterson, K., Friedman, D., Taylor, C., Hong, H., Liu, J., Avigan, M. I., Hayashi, P., Rule, J. A., Lee, W. M., Rakela, J., Feldman, G. M., & Chen, M. (2026). Serum Hepatocyte Growth Factor Predicts Outcomes in Non‐Acetaminophen Drug‐Induced Acute Liver Failure. Liver International, 46(11). https://doi.org/10.1111/liv.70895

Vancouver

Wang T, Bacot SM, Patterson K, Friedman D, Taylor C, Hong H, et al. Serum Hepatocyte Growth Factor Predicts Outcomes in Non‐Acetaminophen Drug‐Induced Acute Liver Failure. Liver International. 2026;46(11). doi:10.1111/liv.70895

BibTeX
@article{Wang2026,
  author = {Wang, Tao and Bacot, Silvia M and Patterson, Kamai and Friedman, Devira and Taylor, Caroline and Hong, Huixiao and Liu, Jie and Avigan, Mark I and Hayashi, Paul and Rule, Jody A and Lee, William M and Rakela, Jorge and Feldman, Gerald M and Chen, Minjun},
  title = {Serum Hepatocyte Growth Factor Predicts Outcomes in Non‐Acetaminophen Drug‐Induced Acute Liver Failure},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1111/liv.70895}
}
Kostenlos starten →